Close Menu

People in the News

Apr 02, 2020

Sera Prognostics: Jay Moyes

Sera Prognostics has appointed Jay Moyes its CFO. He currently is a director on the boards of Achieve Life Sciences, BioCardia, and Puma Biotechnologies. He was at Myriad Genetics for 14 years until he left in 2007 as its CFO.

Apr 02, 2020

Castle Biosciences: Miles Harrison

Castle Biosciences has appointed Miles Harrison to its board of directors effective immediately, expanding the size of the board to eight members. Harrison will stand for election for a three-year term at the company's 2020 annual meeting of stockholders.

Since February 2016, Harrison as served as the North American president and general manager of independent global dermatology company Galderma Laboratories. He has also served as vice president and general manager of Galderma's consumer business unit. Prior to Galderma, Harrison spent most of his career at Novartis, and has held multiple leadership positions of increasing responsibility across the consumer, oncology and pharmaceuticals businesses, most recently as vice president and head of global advocacy.

Apr 01, 2020

Biotheranostics: Matt Sargent

Biotheranostics has promoted its vice president of sales, Matt Sargent, to the position of chief commercial officer. In his new role, Sargent will be responsible for sales, marketing, market access, and customer service, and will lead the company's growth of its core tests: Breast Cancer Index and CancerTYPE ID. Sargent holds over 17 years of experience in the oncology diagnostic space during which he led the launch of Breast Cancer Index at Biotheranostics and the launch of the oncology division of Caris Life Sciences, where he served as vice president of oncology sales.

Mar 31, 2020

Flagship Biosciences: Geoff Metcalf

Flagship Biosciences announced the hiring of Geoff Metcalf as VP of clinical diagnostics, where he will lead the creation and implementation of diagnostic tissue tests. Metcalf has worked in product development, sales and marketing, and business development at companies including Eli Lilly and Beckman Coulter. Most recently he was head of strategic planning at Siemens Diagnostics.

Metcalf earned a bachelor's degree in chemical engineering from Virginia Tech and a master of business administration degree from Harvard.

Mar 30, 2020

Owlstone Medical: Neil Tween

Owlstone Medical has appointed Neil Tween as its CFO. Tween joined Owlstone Medical from GW Pharmaceuticals where he served as vice president and group financial controller. During his tenure, he helped oversee the maturation of the company from a medium-sized partner-funded R&D company to a 900-person global commercial organization. Prior to that, Tween was financial controller at Jagex and spent six years with Deloitte, advising a range of listed and private biotech and pharmaceutical clients.

Mar 25, 2020

Qiagen: Thierry Bernard

Qiagen said this week that it has named Thierry Bernard as CEO. Qiagen's board has also resolved to propose Bernard for election as CEO and managing director at the company's next annual meeting in June. Bernard, who is also senior VP and head of molecular diagnostics at Qiagen, has served as the company's interim CEO since October, when long-time CEO Peer Schatz parted ways with the company. Bernard joined Qiagen in 2015. Prior to that he was senior executive VP of worldwide commercial operations at BioMérieux, where he also managed investor relations for the greater China region.

Bernard is "an outstanding leader who has performed impressively while guiding Qiagen through a period of significant change since taking on this role on an interim basis in October 2019," Håkan Björklund, chairman of Qiagen's supervisory board, said in a statement. "He is a strong and proven leader with extensive industry expertise and deep customer relationships. Most important, he has shown the energy and skill to drive Qiagen forward and has been a key leader in achieving the agreement for Qiagen to be acquired by Thermo Fisher Scientific in a transaction that remains on track for completion in the first half of 2021."

Mar 24, 2020

Exagen Diagnostics: Debra Jeske, Anja Kammesheidt

Exagen Diagnostics has appointed Debra Jeske as its chief medical officer and Anja Kammesheidt as its chief scientific officer. Zack is a board-certified rheumatologist and was previously vice president of clinical development at Xencor. Before that, she was executive director and medical scientific leader for the biotherapeutics development unit at Novartis. She also has held a number of positions in basic research, clinical development, and medical affairs at Amgen.

Kammesheidt was CSO at Ambry Genetics and at Pathway Genoics. She also has held R&D positions at Agendia and Purdue Pharma. She replaces Thierry Dervieux, who has been a consultant to Exagen since he resigned from the company in Q4 2019 to pursue other opportunities. 

Mar 24, 2020

Scipher Medicine: Slava Akmaev

Scipher Medicine has appointed Slava Akmaev as its chief technology officer, a role that includes overseeing the company's data science and technology teams, ensuring efficient data on-boarding, quality control, and rapid analytics across Scipher's pipeline of precision diagnostics.

Akmaev is a leader in applying high-throughput molecular technology, machine learning, artificial intelligence, and data analysis within the life sciences and healthcare industry, and routinely publishes in the peer-reviewed scientific literature. Prior to joining Scipher, he was the senior vice president and chief analytics officer at Berg, where he cofounded and led Berg Analytics. Prior to that he helped commercialize four molecular diagnostic tests at Genzyme Genetics. 

Mar 23, 2020

Myriad Genetics: Louise Phanstiel, John Henderson

Myriad Genetics' board of directors has nominated Louise Phanstiel as its new chair. Phanstiel has served as a director at Myriad since September 2009, has chaired the audit committee and been a member of the nominating and governance committee. She has held various positions at insurer Anthem, and was a partner at PricewaterhouseCoopers. Phanstiel has previously served on the boards of Verastem and Inveresk Research Group.

John Henderson, meanwhile, has resigned as chair of Myriad's board, but will continue to serve as a director. "This change in the leadership of the board is a reflection of the changing environment in which Myriad Genetics operates," Henderson said in a statement. "While the company remains focused on providing critical health care information for the patient, there also is a need to ensure optimization of the processes, which ensure efficient delivery of results, while managing business operations effectively."

Mar 17, 2020

Roche: Jörg Duschmalé, Patrick Frost

Roche has elected Jörg Duschmalé and Patrick Frost to its board of directors, while Andreas Oeri and John Bell have stepped down after 24 and 19 years on the board, respectively. Oeri was the representative of the current shareholder pool.

Duschmalé is a fifth-generation descendant of Roche's founder, and he was a postdoctoral researcher in oligonucleotide chemistry at Roche from 2015 to 2018. Frost has worked at life insurance company Swiss Life in Zurich since 2006, first as Group Chief Information Office and now as Group CEO. He previously served as the global head of fixed income investment at Winterthur Insurance.
Mar 17, 2020

Thrive Earlier Detection: Matt Franklin, Sarah Larson, Semi Trotto

Thrive Earlier Detection has announced the appointment of Matt Franklin as its chief commercial officer, the appointment of Sarah Larson to its board of directors, and Semi Trotto's promotion to chief people officer.

Franklin holds more than 20 years of business, commercial, and strategic marketing experience in the diagnostics, life sciences, and technology industries. Most recently, he served as chief business officer at ArcherDx, where he was responsible for various business development activities. Prior to Archer, he held senior leadership roles at both Foundation Medicine and Boston Scientific.

Larson currently serves as partner and chief human resources officer at Third Rock Ventures where she is responsible for human resources and also provides guidance and counsel to the firm's portfolio companies, focusing on areas of human capital, leadership development, and culture creation. She has more than 20 years of experience in human resources and leadership development.

Trotto, a member of Thrive's founding management team, most recently served as senior vice president and head of human resources. Before joining Thrive, she held leadership positions in human resources at Editas Medicine, Baxalta, and Bristol-Myers Squibb. She has more than 20 years of experience in the field overall.

Mar 13, 2020

NantHealth: Deanna Wise

NantHealth has named Deanna Wise to its board of directors. Wise serves as senior VP and CIO of Phoenix-based Banner Health. Prior to joining Banner a year ago, she was executive VP and CIO of Dignity Health, where she oversaw the implementation of a multi-site electronic health records system and a predictive analytics program.  

Mar 12, 2020

Quest Diagnostics: Wright Lassiter III

Quest Diagnostics announced Wright Lassiter III has been elected to the company's board of directors. Lassiter is the president and CEO of Henry Ford Health System in Michigan, and before that was the CEO of Alameda Health System in Oakland, California. Currently, Lassiter is the board vice chair for the Federal Reserve Bank of Chicago, acts as chair of the bank's governance and nominating committee, and serves on the audit committee. He is also on the boards of LeMoyne College, the Detroit Chamber of Commerce, the Detroit Children's Fund, and the Detroit Regional Partnership. He received a master's degree in healthcare administration from Indiana University, and a bachelor's degree in chemistry from LeMoyne College.

Mar 12, 2020

Sema4: Rachel Sherman

Genetic testing and informatics firm Sema4 has appointed Rachel Sherman to its board of directors.

Sherman is a former principal deputy commissioner of food and drugs at the US Food and Drug Administration. Her career at FDA spanned almost three decades and she oversaw HIV drug development, directed the Critical Path initiative, launched expedited review, and guided the establishment of the oncology center of excellence program.

She is currently a drug development, regulatory, and policy consultant at a firm she founded last year after retiring from FDA, and a lecturer at Harvard Medical School's Department of Population Medicine. She also serves on the board of Aptinyx, a pharmaceutical firm.

Sherman holds an MD from Mount Sinai School of Medicine and a master's degree in public health from Johns Hopkins University.

Mar 11, 2020

Babson Diagnostics: David Stein, Dennis Gilbert, Dave Hickey

Babson Diagnostics has expanded its board of directors to include David Stein as director, Dennis Gilbert as director, and Dave Hickey as observer.

David Stein, former head of global strategy and innovation at Siemens Healthineers, was instrumental in incubating Babson Diagnostics in its earliest days while working alongside Eric Olson, CEO of Babson.

Dennis Gilbert, head of laboratory diagnostics research and development at Siemens Healthineers, leads R&D for its Atellica Solution, the instrument suite used for Babson Diagnostics’ chemistry and immunoassay tests.

Dave Hickey, worldwide president of integrated diagnostic solutions at BD, currently leads its diagnostics businesses, including the specimen management business.

Stein, Gilbert, and Hickey join existing board members Olson; Maninder Kahlon, vice dean for the Health Ecosystem at the University of Texas at Austin Dell Medical School; and Judson Cooper, founding principal with Prism Ventures.

Mar 10, 2020

Thermo Fisher Scientific: Paul Parker

Paul Parker will join Thermo Fisher Scientific as VP of strategy and corporate development, starting April 15. He will join the company from Goldman Sachs, where he was co-chairman of global mergers & acquisitions and a member of the firm's partnership committee. Previously, he held operating and client relationship roles at Goldman Sachs, Barclays, Lehman Brothers, and JP Morgan. Parker has degrees from Harvard Business School and from the University of North Carolina at Chapel Hill.

Mar 10, 2020

Biodesix: Kieran O'Kane, Bobbi Coffin

Biodesix has announced a realignment of its commercial executive team. Effective immediately, current head of strategic marketing Kieran O'Kane will become the company's chief commercial officer, while Bobbi Coffin, currently chief marketing officer, will become the firm's chief growth officer.

After joining the company in 2018, Biodesix said that O'Kane played a leading role in the successful acquisition of Integrated Diagnostics and Oncimmune's laboratory and incidental pulmonology nodule malignancy test, proving instrumental in the subsequent commercial launch of what are now the Nodify XL2 and Nodify CDT tests. He previously worked at various other companies, including NanoString Technologies, Bristol Myers Squibb, and Roche.

Coffin joined Biodesix in 2015 from Exact Sciences where she was VP of commercial marketing and strategy. Prior to that role, she held leadership positions at Precision Therapeutics and Cytyc/Hologic.

Mar 10, 2020

Fulgent Genetics: Brandon Perthuis

Fulgent Genetics has promoted Brandon Perthuis to chief commercial officer from VP of commercial operations. He will continue to lead the company's global sales organization and commercialization effort and will report to CEO Ming Hsieh. Perthuis came to Fulgent in 2017. He carries 16 years of experience in clinical genetics, including a stint as VP of sales and marketing at Baylor Genetics.

Mar 09, 2020

Centogene: Dirk Ehlers

Centogene said that COO and President Dirk Ehlers will leave the company for personal reasons after the annual general meeting in June. He has been a member of the executive management board for two years. He joined Centogene in April 2018 from Hill-Rom Holdings. Prior to that, he was CEO of Eppendorf, and he held management positions at Roche, Fresenius Kabi, Olympus Optical, and Evotec.

Mar 02, 2020

PerkinElmer: Michel Vounatsos

PerkinElmer has appointed Michel Vounatsos to its board of directors, effective March 1. He is currently CEO of Biogen. Before that, he was at Merck, where he held several leadership positions, including president of the Primary Care Customer Business Line and Merck Customer Centricity. Earlier in his career, he held management positions at Ciba-Geigy. 

Feb 26, 2020

Thermo Fisher Scientific: Marc Casper, Jim Manzi, Thomas Lynch

Thermo Fisher Scientific's board of directors has elected Marc Casper its chairman, effective immediately. Casper, who is the company's president and CEO, succeeds Jim Manzi, who will continue to serve as a director on Thermo Fisher's board. Manzi has been a director at the company since May 2000 and was chairman of the board for 15 years. Also, Thomas Lynch has been elected as lead independent director, effective immediately. He has been a board member since May 2009. 

Feb 25, 2020

Centogene: Vaibhav Joshi

Centogene has named Vaibhav Joshi to the newly created role of chief data officer. He joins the company from Virgin Care, which provides health and social care services in the UK. He was chief data officer there. Before that Vaibhav was clinical informatics director at the Private Healthcare Information Network and clinical analytics lead at Ramsay Health Care UK. 

Feb 25, 2020

Guardant Health: Derek Bertocci

Guardant Health said that Derek Bertocci will be retiring as the company's chief financial officer during the second quarter of 2020. He will continue to serve in his current role until a successor is hired and plans to remain at Guardant and support the firm during this transition.

Feb 18, 2020

Proscia: Arun Ananthapadmanabhan

Proscia appointed Arun Ananthapadmanabhan its executive vice president of global growth to manage the company's international commercial operations. He joins the Philadelphia-based digital pathology firm from Philips, where he created and led the computational pathology business. Ananthapadmanabhan will be based in Amsterdam. 

Feb 14, 2020

Biocept: Cory Dunn

Biocept has promoted Cory Dunn to Senior VP of commercial operations, succeeding Edwin Hendrick, who resigned to pursue other endeavors. Dunn previously served as Biocept's VP of commercial operations, beginning in October 2018. Prior to joining Biocept, she held multiple leadership positions at life sciences companies specializing in diagnostics, including GenomeDx Biosciences (presently Decipher Biosciences), PLUS Diagnostics (presently Inform Diagnostics) and Genoptix.  She holds an MA in education from Stanford University, and an MS in biology and BS in Biochemistry and Cell Biology from the University of California, San Diego.

Pages